Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

Figures & data

Table 1. Simulated AFN-1252 doses and corresponding free drug area under the concentration time curve to minimum inhibitory concentration (MIC) ratio over MIC (fAUC/MIC) parameters in the in vitro pharmacodynamic model

Dose (mg)	fAUC/MIC
	Dosing q12h	Dosing q24h
4·2	39	—
9·4	78	39
18·8	156	78
37·5	312	156
56·2	468	—
75·0	625	312
112·5	938	468
225	—	938
450	—	1875

Figure 1. In vitro pharmacodynamic model experiments of (A) AFN-1252 q24h versus ATCC 29213, (B) AFN-1252 q12h versus ATCC 29213, (C) AFN-1252 q24h versus MRSA S186 and (D) AFN-1252 q12h versus MRSA S186.